News

Encouraging news from Isis Pharmaceuticals, Inc., presented at the 19th International World Muscle Society Congress in Berlin, demonstrated the efficacy of ISIS-SMNRx in treating spinal muscular atrophy (SMA) in infants and children. Results were from the ongoing open-label Phase 2 clinical trial. Isis is also enrolling patients in the…

A recent study entitled “iPSC-Derived Neural Stem Cells Act via Kinase Inhibition to Exert Neuroprotective Effects in Spinal Muscular Atrophy with Respiratory Distress Type 1” published in Stem Cell Reports suggests therapeutic potential of neural stem cells (NSCs) from human-induced pluripotent stem cells (iPSCs) to…

Spinal muscular atrophy is a disease characterized by a short lifespan and progressive, debilitating symptoms. New research on mice, however, suggests that scientists may in the early stages of developing a new treatment that could eventually extend survival rates in children with SMA. A new study entitled “…

Parents want what is best for their children, and parents of children with spinal muscular atrophy (SMA) are no exception. At times, these parents can feel stressed about their children’s medical condition, and any way that stress can be alleviated is vital to improving parent outlook on managing their children’s…